tools_research.jpg
Research Unsere Klienten profitieren von
Industrie-Expertise und M&A-Erfahrung
gradient
Pharma-Produktionsstätten – eine interaktive Karte
Wir haben eine interaktive Karte aller FDA- und EMA-zertifizierten Anlagen zur Produktion, Analyse, Verpackung und Distribution von Pharmazeutika erstellt (click auf die Karte rechts).

Die Karte zeigt den ungefähren Ort von ca. 24'000 Anlagen (9'800 von FDA, der Rest von EMA zertifiziert), wobei FDA- und EMA-Zertifizierungen einzeln gezählt werden – eine Anlage mit FDA und EMA-Zertifizierung erscheint also doppelt. Anlagen können nach Regulator (FDA oder EMA), Zertifikats-Typ (GMP oder GDP für EMA; feiner aufgeteilt für FDA) und nach Stichwort gesucht werden. Die Mausspitze zeigt jeweils alle Details der Anlage an.

Die Daten wurden im März 2017 von www.fda.org und der EUDRA-Datenbank von EMA bezogen und mithilfe des Google Geocoding Services mit Koordinaten versehen.
Market Reports
About growth and strategies in the CDMO business

The pharma outsourcing market promises robust and attractive growth although with differences in...

An interactive map of digital healthcare

Much has been written recently about wearable sensors, health apps, digital pills, artificial...

The emerging landscape of digital healthcare

Pharma M&A Report 2018

KP publishes the seventh edition of its report M&A activity and major trends in the Pharma industry....

An interactive global map of Pharma manufacturing sites

CMOs have been very active in M&A in the last few years, driving consolidation among CMOs, but...

What drives Mergers & Acquisitions in the Pharma industry?

The pharmaceutical industry probably sees more M&A activity than any other industry, both in the...

How to sell a pharma brand

Selling and buying established products has long been a standard part of the business development of...

The emerging landscape of digital healthcare

Much has been written recently about wearable sensors, health apps, digital pills, artificial...

The year in review 2016: Cooling down - or the calm before the storm?

M&A in the Pharma industry went through a cooling phase in 2016. After a very hectic phase in 2014...

Global Pharma/Biotech M&A Report 2016

Das Jahr 2015 kann für die Pharma und Biotech-Industrie mit drei Begriffen zusammengefasst werden:...

Global Pharma/Biotech M&A Report 2015

The 2015 edition of the Global Pharma Biotech M&A Report features: A global overview about the...

Global Pharma & Biotech M&A Report 2014

The "Global Pharma & Biotech M&A Report 2014" highlights trends and strategic shifts in the global...

China: Sailing in Choppy Waters

Read in this report from InterChina Consulting (IMAP China) about crucial implications of China's...

M&A in China - A Corporate Survey by InterChina

M&A transactions in China are around 5% of global activity while two thirds of all transactions are...

Strategies for the China Oncology Market

This report from InterChina Consulting (IMAP China) provides insights and strategies for...

Global Pharma & Biotech M&A Report 2013

IMAP's Global Pharma & Biotech M&A Report 2013 contains regional reviews and highlights on M&A...

CEIBS 'Business in China' Survey 2013

This InterChina (IMAP China) report, based on a survey from CEIBS, documents the perceived business...

Investment Opportunities in China's Eldercare Industry

China's "aging society" offers interesting investment opportunities for the healthcare sector. This...

Vitamins, Minerals & Supplements: M&A Summary

Demand for VMS doesn't just come from consumers - corporates and private equity houses have been...

Global Pharma & Biotech M&A Report 2012

Review of 2011 M&A deals, including Gilead/Pharmasset: anatomy of a billion-dollar R&D deal. And:...

China: Diagnosis for Growth - Global Pharma Companies Face Layoffs

After 2006, global Pharma restructured their China businesses. Within just five years, the game has...

China: The Mixed Effects of Healthcare Reform in Rural Areas

InterChina Consulting (IMAP China) studied the effects of the healthcare reform in rural areas, and...

Healthcare Equipment & Supplies Global Report 2011

Whilst the global economic crisis and the reduction in healthcare expense reimbursement have had a...

China Healtchare System - a Phoenix from the Ashes

In April 2009, the government announced a RMB 850bn (USD 124bn) program to overhaul the...

China: A mistery for Big Pharma Companies

InterChina Consulting (IMAP China) interviewed William Keller, former Country Manager of Roche, to...

India: Fragmented Hospital Sector to Grow by 27% p.a.

The Indian hospital sector, currently worth USD 25bn, is anticipated to grow by 27% p.a., finds an...

China: The Healthcare System at a Turning Point

The release of the Healthcare reform plan in April 2009 marks a turning point in the long-neglected...

An interactive map of digital healthcare

Much has been written recently about wearable sensors, health apps, digital pills, artificial...